Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.

DURAN AS; LOSSO MH; SALOMON H; HARRIS DR; PAMPURO S; SOTO-RAMIREZ LE; DUARTE G DE SOUZA RS; READ JS

AIDS - AN INTERNATIONAL MONTHLY JOURNAL

LIPPINCOTT WILLIAMS & WILKINS

Año: 2007 vol. 21 p. 199 - 205

0269-9370

To quantify primary resistance mutations (PRMs) among HIV-1-infected women receiving antiretroviral therapy (ART) for prevention of mother-to-child transmission (MTCT). Methods: Peripheral blood mononuclear cell samples from HIV-1-infected women enrolled in a prospective cohort study in Argentina, the Bahamas, Brazil, and Mexico (NISDI Perinatal Study) were assayed for PRMs. Eligible women were those enrolled by March 2005 and diagnosed with HIV-1 infection during the current pregnancy, and who received ART for MTCT prophylaxis and were followed for 6?12 weeks postpartum.